Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,007 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 31,007 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 750 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse/Cust Son | 400 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 1,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $595.43 | $833,602.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 26 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,615 F21 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on August 24, 2020 at prices ranging from $595.15 to $595.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $594.30 | $832,020.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 25 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,015 F20 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on August 24, 2020 at prices ranging from $594.01 to $594.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $593.11 | $118,622.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 24 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,415 F19 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 24, 2020 at prices ranging from $593.06 to $593.15. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,741 | $592.27 | $3,400,222.07 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 23 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,615 F18 · price: Represents volume-weighted average price of sales of 5,741 shares of Company stock on August 24, 2020 at prices ranging from $592.00 to $592.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 188 | $597.46 | $112,322.48 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 22 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,356 F17 · price: Represents volume-weighted average price of sales of 188 shares of Company stock on August 24, 2020 at prices ranging from $597.17 to $598.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $596.63 | $656,293.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 21 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,544 F16 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on August 24, 2020 at prices ranging from $596.15 to $596.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,607 | $595.43 | $956,856.01 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 20 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,644 F15 · price: Represents volume-weighted average price of sales of 1,607 shares of Company stock on August 24, 2020 at prices ranging from $595.05 to $596.03. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,201 | $594.30 | $713,754.30 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 19 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,251 F14 · price: Represents volume-weighted average price of sales of 1,201 shares of Company stock on August 24, 2020 at prices ranging from $594.01 to $594.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,037 | $177.82 | $1,784,779.34 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 18 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,963 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-20-000098 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,037 Underlying: Common Stock · 4,963 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-20-000098 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,800 | $605.05 | $5,929,490.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 17 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,415 F13 · price: Represents volume-weighted average price of sales of 9,800 shares of Company stock on August 21, 2020 at prices ranging from $605.00 to $605.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2020 at each separate price. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $608.15 | $121,630.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 16 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,215 Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,663 | $605.04 | $5,846,501.52 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 15 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,415 F12 · price: Represents volume-weighted average price of sales of 9,663 shares of Company stock on August 21, 2020 at prices ranging from $605.00 to $605.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2020 at each separate price. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $57.11 | $285,550.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 14 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $608.06 | $182,418.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 13 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,078 F11 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 21, 2020 at prices ranging from $608.01 to $608.15. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2020 at each separate price. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,963 | $177.82 | $882,520.66 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 12 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-20-000098 · edgardoc.xml · derivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 560 | $619.33 | $346,824.80 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 11 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,415 F10 · price: Represents volume-weighted average price of sales of 560 shares of Company stock on August 20, 2020 at prices ranging from $619.21 to $619.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,152 | $618.57 | $712,592.64 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 10 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,975 F9 · price: Represents volume-weighted average price of sales of 1,152 shares of Company stock on August 20, 2020 at prices ranging from $618.15 to $619.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,371 | $617.68 | $2,082,199.28 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 9 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,127 F8 · price: Represents volume-weighted average price of sales of 3,371 shares of Company stock on August 20, 2020 at prices ranging from $617.15 to $618.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,627 | $616.26 | $1,002,655.02 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,498 F7 · price: Represents volume-weighted average price of sales of 1,627 shares of Company stock on August 20, 2020 at prices ranging from $616.00 to $616.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,290 | $615.48 | $2,024,929.20 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,125 F6 · price: Represents volume-weighted average price of sales of 3,290 shares of Company stock on August 20, 2020 at prices ranging from $615.00 to $615.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $57.11 | $571,100.00 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 703 | $619.29 | $435,360.87 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,415 F5 · price: Represents volume-weighted average price of sales of 703 shares of Company stock on August 20, 2020 at prices ranging from $619.15 to $619.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,318 | $618.49 | $815,169.82 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,118 F4 · price: Represents volume-weighted average price of sales of 1,318 shares of Company stock on August 20, 2020 at prices ranging from $618.15 to $619.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,454 | $617.64 | $2,133,328.56 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,436 F3 · price: Represents volume-weighted average price of sales of 3,454 shares of Company stock on August 20, 2020 at prices ranging from $617.15 to $618.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,742 | $616.25 | $1,073,507.50 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,890 F2 · price: Represents volume-weighted average price of sales of 1,742 shares of Company stock on August 20, 2020 at prices ranging from $616.01 to $616.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,783 | $615.51 | $2,328,474.33 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,632 F1 · price: Represents volume-weighted average price of sales of 3,783 shares of Company stock on August 20, 2020 at prices ranging from $615.00 to $615.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2020 at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · derivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $650.00 | $975,000.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 4,700 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $651.09 | $130,218.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 400 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on July 7, 2020 at prices ranging from $651.02 to $651.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 7, 2020 at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $650.32 | $520,256.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 600 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on July 7, 2020 at prices ranging from $650.00 to $650.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 7, 2020 at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $650.00 | $325,000.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 1,150 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,500 | $650.00 | $4,875,000.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,415 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,500 | $33.42 | $250,650.00 |
DisclosureSEC source: 0001237899-20-000029 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $609.37 | $914,055.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 6,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $609.68 | $60,968.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 1,400 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 100 shares of Company stock on June 29, 2020 at prices ranging from $609.65 to $609.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price. Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $608.29 | $304,145.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 1,500 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on June 29, 2020 at prices ranging from $608.14 to $608.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price. Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $607.54 | $121,508.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 2,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $606.80 | $121,360.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 2,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 29, 2020 at prices ranging from $606.69 to $606.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 29, 2020 at each separate price. Read SEC document |
| June 29, 2020 Filed Jun 29, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $609.37 | $304,685.00 |
DisclosureSEC source: 0001237899-20-000027 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 1,650 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $595.00 | $297,500.00 |
DisclosureSEC source: 0001237899-20-000021 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 7,700 Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $598.02 | $299,010.00 |
DisclosureSEC source: 0001237899-20-000021 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 2,400 F1 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on May 29, 2020 at prices ranging from $598.00 to $598.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 29, 2020 at each separate price. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $578.00 | $289,000.00 |
DisclosureSEC source: 0001237899-20-000021 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 8,200 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $580.00 | $290,000.00 |
DisclosureSEC source: 0001237899-20-000021 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 2,900 Read SEC document |
| May 13, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,000 | $580.00 | $2,900,000.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,415 Read SEC document |
| May 13, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $33.42 | $167,100.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $575.00 | $172,500.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 8,700 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.